Please Wait
Applying Filters...
menu
    • menu
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Together we can improve the quality of life

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Mitomycin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 313,931Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ZUSDURI Gains Permanent J-Code, Boosting Bladder Cancer Access
    ZUSDURI Gains Permanent J-Code, Boosting Bladder Cancer Access

    05 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/05/3212696/0/en/Permanent-J-Code-for-ZUSDURI-Now-in-Effect-Expanding-Patient-Access-to-Innovative-Bladder-Cancer-Therapy.html

    GLOBENEWSWIRE
    05 Jan 2026
    Share Share
    Urogen Pharma Issues Inducement Grants Per Nasdaq LR 5635(C)(4)
    Urogen Pharma Issues Inducement Grants Per Nasdaq LR 5635(C)(4)

    05 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/05/3200660/0/en/UroGen-Pharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    05 Dec 2025
    Share Share
    UroGen Unveils Q3 2025 Financials Amid Zusduri Launch Surge
    UroGen Unveils Q3 2025 Financials Amid Zusduri Launch Surge

    06 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/06/3182531/0/en/UroGen-Reports-Third-Quarter-2025-Financial-Results-as-ZUSDURI-Launch-Gains-Momentum.html

    GLOBENEWSWIRE
    06 Nov 2025
    Share Share
    UroGen Publishes Ph3b Study on Home Use of ZUSDURI in NMIBC
    UroGen Publishes Ph3b Study on Home Use of ZUSDURI in NMIBC

    28 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/28/3122406/0/en/UroGen-Announces-Publication-of-Phase-3b-Study-Results-Demonstrating-the-Feasibility-of-Home-Instillation-of-ZUSDURI-for-Recurrent-Low-Grade-Intermediate-Risk-Non-Muscle-Invasive-B.html

    GLOBENEWSWIRE
    28 Jul 2025
    Share Share
    UroGen's 5-Year OPTIMA II Trial Shows ZUSDURI's in Bladder Cancer
    UroGen's 5-Year OPTIMA II Trial Shows ZUSDURI's in Bladder Cancer

    21 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/21/3118671/0/en/UroGen-Announces-Five-Year-Long-Term-Extension-Study-of-the-OPTIMA-II-Trial-Demonstrates-Long-Term-Durability-of-Response-to-ZUSDURI-in-Patients-with-Low-Grade-Intermediate-Risk-No.html

    GLOBENEWSWIRE
    21 Jul 2025
    Share Share
    UGN-103 medac CDMO Enables Clinic Progress in Ph3 UTOPIA Trial
    UGN-103 medac CDMO Enables Clinic Progress in Ph3 UTOPIA Trial

    21 Jul 2025

    // PRESS RELEASE

    https://www.medac-cdmo.com/news-events/newsroom/ugn-103-medac-cdmo

    PRESS RELEASE
    21 Jul 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.